Evaluation of Vaccination Coverage and Determinants of Success of the COVID-19 Vaccination Program Among Populations in Very Precarious Situations (PREVAC)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05075941 |
Recruitment Status :
Not yet recruiting
First Posted : October 13, 2021
Last Update Posted : October 19, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The main objective of the study is to assess the level of vaccination coverage (VC) against COVID-19 among migrants, homeless and travelling community, according to their living conditions and housing.
The secondary objectives are :
- to compare the estimated level of vaccination coverage in the different sites and strata (emergency shelters/hotels, camps, workers' hostels, on the street) with the estimated level in the general population of the same territory obtained from the French Health Insurance data (SIVAC).
- identify the obstacles and leverage of vaccination (i.e. mobile team) according to living conditions and habitat (socio-demographic factors, personal health history, vaccine adherence, local health policies, etc.).
Condition or disease | Intervention/treatment |
---|---|
COVID-19 | Other: Vaccination coverage |
Study Type : | Observational |
Estimated Enrollment : | 3470 participants |
Observational Model: | Other |
Time Perspective: | Cross-Sectional |
Official Title: | PREVAC: Evaluation of Vaccination Coverage and Determinants of Success of the COVID-19 |
Estimated Study Start Date : | November 2021 |
Estimated Primary Completion Date : | December 2021 |
Estimated Study Completion Date : | February 2022 |

Group/Cohort | Intervention/treatment |
---|---|
Shelters Paris/93 |
Other: Vaccination coverage
proportion of people declaring to have received at least one dose of vaccination against COVID-19 among target population |
Workers' hostels Paris/93 |
Other: Vaccination coverage
proportion of people declaring to have received at least one dose of vaccination against COVID-19 among target population |
travelling community IDF(77/93/95) |
Other: Vaccination coverage
proportion of people declaring to have received at least one dose of vaccination against COVID-19 among target population |
Street/Camps Paris/93 |
Other: Vaccination coverage
proportion of people declaring to have received at least one dose of vaccination against COVID-19 among target population |
Covid Homeless and migrants Marseille |
Other: Vaccination coverage
proportion of people declaring to have received at least one dose of vaccination against COVID-19 among target population |
Hostel Paris/93 |
Other: Vaccination coverage
proportion of people declaring to have received at least one dose of vaccination against COVID-19 among target population |
- Vaccination coverage among COVID-19 [ Time Frame: one month ]Assess the proportion of people declaring to have received at least one dose of vaccination against COVID-19 among migrants, homeless and travelling community, according to their living conditions and housing
- Identify the most appropriate conditions for the use of vaccination against COVID-19 [ Time Frame: one month ]Promote interventions to encourage the use of COVID-19 vaccination

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Adult (18 years and older)
- People considered as homeless (homeless, living in a camp or squat) or
- Living in adapted housing (migrant workers' hostel) or
- Housed in residences of the National System or
- Housed in a social residence such as a 115 hotel or a social housing centre
- Freely and voluntarily consenting to participate
Exclusion Criteria:
- Refusal to participate in the study (non-consent).
- Language barrier with no in-person or telephone translation available.
- Impossibility to give free and informed consent (comprehension barrier, cognitive and/or psychiatric and/or addictive disorders, external pressure from family and friends, persons under guardianship, etc.).

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05075941
Contact: Thomas ROEDERER | +33 1 40 21 55 55 | thomas.roederer@epicentre.msf.org | |
Contact: Jessica SAYYAD | +33 1 40 21 55 55 | jessica.sayyad@epicentre.msf.org |
Principal Investigator: | Elisabeth POULET, MD | Epicentre |
Responsible Party: | Epicentre |
ClinicalTrials.gov Identifier: | NCT05075941 |
Other Study ID Numbers: |
2021-A01960-41 |
First Posted: | October 13, 2021 Key Record Dates |
Last Update Posted: | October 19, 2021 |
Last Verified: | October 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | The results will be presented in a report to the Ministry of Health, the Haute Autorité de Santé and the various partners. The main findings of this study could potentially be compared with the findings of other ongoing studies, once they are completed. An abstract of the findings will be submitted for presentation at a scientific conference, and at least one manuscript will be submitted for publication in a peer-reviewed scientific journal. |
Supporting Materials: |
Study Protocol Statistical Analysis Plan (SAP) Informed Consent Form (ICF) Clinical Study Report (CSR) |
Access Criteria: | Study partners |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
vaccination coverage migrants homeless travelling community |
COVID-19 Respiratory Tract Infections Infections Pneumonia, Viral Pneumonia Virus Diseases |
Coronavirus Infections Coronaviridae Infections Nidovirales Infections RNA Virus Infections Lung Diseases Respiratory Tract Diseases |